Company profile
Immunic, Inc. logo

Immunic, Inc.

Pipeline3 assets

  • Vidofludimus calciumIMU-838 / DHODH inhibitor and Nurr1 activator / Oral small molecule / Multiple sclerosis
    Relapsing multiple sclerosisPhase 3Ongoing (ENSURE-1/2 fully enrolled; top-line data expected end 2026)GlobalProgressive multiple sclerosisPhase 2Completed (CALLIPER positive; PPMS Phase 3 initiation expected 2026)North AmericaEurope
  • IMU-856IMU-856 / SIRT6 modulator / Oral small molecule / Gastrointestinal diseases
    Celiac diseasePhase 1bCompleted (positive proof-of-concept)Global
  • IMU-381IMU-381 / Nurr1 / Oral small molecule / Autoimmune diseases
    Neurologic, gastrointestinal and other autoimmune diseasesPreclinicalPreclinical

Latest news12 items

All news

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

– Late-Breaking Poster Introduces New Unified Statistical Analyses for Assessing Confirmed Disability Changes for Trials in Progressive Multiple Sclerosis – – Additional CALLIPER Data Further Highlight Vidofludimus Calcium’s Favorable Safety and Tolerability Profile;...

Presentation / Abstract • Phase 2CMSC poster presentation Thu, May 28, 2026, 5:00 PM ET

Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

– Appointed Globally Renowned Biopharmaceutical Executive and Neurology Drug Developer, Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer – – Continued to Execute Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis, with Top-Line Data Expected by End of 2026 – – Raised $200 Million in an Oversubscribed Private Placement,...

Presentation / Abstract • Phase 2ACTRIMS Forum 2026 poster presentations Fri, Feb 27, 2026

Immunic to Participate in Investor and Medical Conferences in May

NEW YORK, April 30, 2026 – Immunic, Inc. (Nasdaq: IMUX) , a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor and medical conferences in May: May 4-6 and 12-13: 26th Bio€quity Europe ....

Presentation / Abstract • Phase 2

Immunic, Inc. Announces 1-for-10 Reverse Stock Split

NEW YORK, April 23, 2026 – Immunic , Inc. (Nasdaq: IMUX) , a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases (the “Company” or “Immunic”), today announced that it will effect a reverse stock split of its outstanding shares of common stock, effective as of 12:01 a.m. Eastern Time on April 27, 2026....

Immunic to Participate in Scientific and Medical Conferences in April

NEW YORK, April 9, 2026 – Immunic, Inc.(Nasdaq: IMUX) ,a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following scientific and medical conferences in April: April 14-16: 8th Annual Neuroimmunology Drug Development Summit ....

Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement

NEW YORK, April 1, 2026 – Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that it received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on March 27, 2026, informing the company...

Immunic to Participate in Investor Conferences in March

NEW YORK, March 3, 2026 – Immunic , Inc. (Nasdaq: IMUX) ,a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced participation in the following investor conferences in March: March 8-11: Leerink Partners Global Healthcare Conference....